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and Antonio Ibarra
Abstract
Spinal cord injury (SCI) is an important pathology leading to possibly fatal 
consequences. The most common repercussions are those affecting motor and 
sensitivity skills. SCI-damage occurs in its first phase—as a result of the lesion 
mechanism (contusion, compression, transection, and primary lesion). After this 
primary damage, there is a second phase with further deleterious effects on neural 
degeneration and tissue restoration. At the moment, several investigation groups 
are working on developing therapeutic strategies to induce neuroprotection. This 
chapter pretends to introduce the reader to a wide range of these therapies, particu-
larly those with promising results and tested in preclinical and clinical studies. In 
the first section, physiopathology of SCI will be addressed. Afterwards, the chapter 
will review neuroprotective strategies such as cyclooxygenase, calpain, and apopto-
sis inhibitors. Finally, the effect of immunophilin ligands, neural-derived peptides, 
antioxidants, hypoglycemic agent, gonadal hormones, Na channel blockers, and 
transplant of cultured cells will also be reviewed.
Keywords: neuroprotection, SCI, therapies, acute phase
1. Introduction
Spinal cord injury (SCI) can be defined as damage to the spinal cord (SC). It 
causes anatomical and physiological changes that result in permanent or temporary 
alterations in its function [1]. The injury causes ionic deregulation, edema, isch-
emia, bleeding, free radicals production, and a generalized inflammatory response 
that will cause partial or total loss of sensitive and motor function below the site of 
injury [2, 3].
In the United States, there are around 17,500 new cases of SCI per year, with an 
approximate prevalence of 280,000 people [4]. SCI is found most frequently in men 
(79.8%) than women (20.2%) and the age distribution reflects a bimodal perfor-
mance with a peak between 15 and 29 years of age and another one on ages above 
50 years [4–6]. Traffic accidents are the main cause of traumatic SCI (38%), and 
they are most prevalent in young people. The low impact accidents like falls are the 
second cause of SCI (31%), and they are more common among people older than 
60 years old [5]. In Mexico, the estimated annual incidence of SCI is about 18.1 per 
million inhabitants. Statistically, the number of people involved rises each year [7].
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2. Pathophysiology
The Spinal Cord Injury could be divided by its etiology in traumatic and 
nontraumatic. The traumatic type is caused by physical damage (traffic accident, 
sportive, and fall), whereas nontraumatic is occasioned by an illness/sickness, such 
as tumors, infections or degenerative diseases which directly affect the SC [8]. In 
addition, SCI can be divided into primary and secondary injury [1, 9].
Primary injury is caused at the moment of physical damage and leads to irre-
versible affection on gray matter during the first hour post-lesion. There are three 
main mechanisms of injury: contusion, when there is not a visible alteration in its 
morphology, producing a necrotic region at the injury area; laceration or transec-
tion, when there is an extreme trauma or penetration, affecting SC conduction of 
nervous impulses depending on whether the tissue is partial or totally transected; 
compression from vertebral fractures leading ischemic damage in the area where 
blood flow was disrupted [10, 11].
After injury, superficial blood vessels undergo to vasospasm which provokes 
damage in the microvasculature of gray matter [12]. Reduction in the perfusion has 
two important implications: hypoxia and ischemia; which may involve to neuro-
genic shock characterized by arterial hypotension, bradycardia, arrhythmia, and 
intraparenchymal hemorrhage that causes neuronal death by necrosis. Afterwards, 
primary injury provokes the rupture of blood brain barrier and a cascade of 
destructive secondary phenomena leading to a further damage in SC and neurologi-
cal dysfunction [1, 13]. Therefore, the primary lesion results in the development of 
a succession of cellular and molecular changes that alter gene expression patterns, 
which are processes that are already part of the secondary injury [11, 12]. During 
the acute phase, injury to the blood vessels and severe hemorrhages cause massive 
influx of inflammatory cells, cytokines, and vasoactive peptides. This phase is 
almost characterized by ionic deregulation that leads to edema, thus interrupting 
the conduction of nerve impulses. Following, subacute phase involves a sequence 
of events like ischemia, vasospasm, thrombosis, inflammatory response, free 
radicals (FR) production, lipid peroxidation (LPO), and activation of autoimmune 
responses causing apoptosis. The huge inflammatory responses after the acute and 
subacute phase, together with the disruption of the blood-brain barrier (BBB), con-
tribute to the progressively swelling of the SC. This generalized edema may increase 
the mechanical pressure of the SC, aggravating the injury [1, 11, 14].
To counteract all these acute effects after SCI, neuroprotective strategies have 
been investigated to rapidly intervene decreasing the neuronal death occurring 
after damage mechanisms. Many pharmacological and nonpharmacological thera-
pies have been developed, and others are still under investigation, this in order to 
improve the quality of life of patients.
3. Neuroprotective therapy after acute SCI
As we review previously, SCI leads to motor and sensory dysfunction, first with 
the primary mechanical injury and then with the complex cascade of secondary 
damaging events [15]. For several years, basic science, preclinical, and clinical stud-
ies are focused in overcoming elements involved in accurate recovery from SCI [1]. 
An ideal neuroprotective therapy must reduce neurological symptoms including 
degenerative changes; starting from there, we can discriminate between potential 
clinical therapies, which could have a better effect [16]. While these therapies are 
being searched, there are many preclinical and clinical investigations exploring 
pharmacological and nonpharmacological treatments.
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3.1 Preclinical pharmacological therapies
This range of therapeutic approaches includes: ionic channel blockers, inhibitors 
of NMDA and AMPA-kainate receptors, inhibitors of FR and LPO, anti-apoptotic 
drugs, calpain inhibitors, immunosuppressive or immunomodulatory drugs, immu-
nophilin ligands, immunomodulatory peptides, hypoglycemic agents, and gonadal 
hormones.
3.1.1 Ionic channel blockers
3.1.1.1 Sodium
3.1.1.1.1 Tetrodotoxin
Tetrodotoxin (TTX) is a low-molecular-weight guanidine neurotoxin that acts as a 
specific blocker of voltage-gated sodium (NaV) channel [17]. TTX has neuroprotec-
tive properties by blocking NaV channels, preventing neuronal death by diminishing 
depolarization, cellular Na+/Ca+2 exchange, and neuronal glutamate release [18].
The beneficial effects of TTX in preclinical studies include a reduction of white 
matter loss after SCI [17–19], promoting a motor function restoration. The effect 
of TTX is time-dependent [20]. The administration of TTX 15 minutes after a SCI 
helps to restore the function of hindlimbs [21]. Despite these promissory effects, 
there are some limitations for the use of TTX in patients, one of them is its toxicity. 
This may appear as a consequence of its systemic distribution and it can involve the 
blocking of diaphragmatic nerves ending in respiratory tract paralysis [17]. Even 
with previous findings, current studies are needed to improve its use in SCI.
3.1.1.1.2 Riluzole
Riluzole is a benzothiazole anticonvulsant drug with neuroprotective effects in 
the SCI [22]. One of the mechanisms by which riluzole operates is the inhibition 
in the presynaptic terminals of glutamate, and this helps to limit the glutamate-
induced toxicity [23]. In addition, riluzole blocks the NaV-gated channels, avoiding 
swelling and neuronal acidosis. Riluzole blocks the entry of H+ to the neurons 
through the Na+/H+ exchanger; this prevents the Ca+2 from inducing the release 
of glutamate and excitotoxicity [22]. Investigations have shown that the inter-
ruption of events associated with glutamate release on the presynaptic space by 
reducing Ca+2 influxes provokes a glutamate-mediated LPO reduction [23, 24]. 
Administration of riluzole within 12 hours of SCI was well tolerated and suggests 
that it may have a beneficial effect on motor outcome [25].
3.1.1.2 Calcium
3.1.1.2.1 Nimodipine
Nimodipine is a dihydropyridinic Ca+2 channel antagonist that boosts the brain’s 
blood flow, without compromising metabolism [26, 27]. It reduces malondialdehyde 
(MDA) levels, ED-1 markers for activated macrophages and myeloperoxidase 
(MPo). Studies have shown that nimodipine helps reducing FR, oxidative damage, 
resulting in the reduction of the damaged area and the infiltration of the inflam-
matory cells to the region, allowing SCI restoration [26]. Furthermore, the effect of 
inhibiting Ca+2 flux by nimodipine reduces apoptosis and tissue damage after SCI, 
increasing cell viability [27].
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3.1.2 Inhibitors of NMDA and AMPA-kainate receptors
3.1.2.1 Memantine
Memantine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antag-
onist, which through the inhibition of hypoxic or ischemic damage/necrosis helps 
to prevent the secondary damage in SCI [28, 29]. The use of an NMDA antagonist 
limits neuronal glutamate exposure caused by excitatory amino acid neurotransmit-
ters [29]. The use of memantine with anti-apoptotic agents like Q-VD-OPh boosts 
the neuroprotective effect through the reduction in apoptosis and necrosis mecha-
nisms. Moreover, it provides better clinical and histological outcomes by limiting 
neuronal necrosis [28, 29].
3.1.2.2 Gacyclidine
Gacyclidine is a noncompetitive NMDA antagonist that is able to reduce the 
extension of ischemic lesions in SCI. It has been proven that gacyclidine is efficient 
in enhancing the functional and histological condition of the injury, but their 
neuroprotective effects are time and dose-dependent [30, 31].
3.1.2.3 NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzoquinoxaline)
NBQX is an AMPA/kainate antagonist that during acute SCI improves mito-
chondrial function and diminishes reactive oxygen species (ROS) formation as well 
as LPO production [32, 33]. The treatment with NBQX reduces white matter loss 
following SCI. Further studies are needed to know more about its efficacious effects 
in acute SCI.
3.1.3 Inhibitors of free radicals and lipid peroxidation
3.1.3.1 Polyunsaturated fatty acids (PUFAs)
Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) are structural compounds of the 
phospholipid membrane. They produce beneficial effects in neurodegenerative dis-
eases by its anti-inflammatory, antioxidant, and membrane stabilizing properties [34]. 
ω-3 PUFAs, particularly docosahexaenoic acid (DHA), exert profound anti-inflamma-
tory effects on the central nervous system (CNS), confer significant protection to the 
white matter, and help to increase neurite growth and synapse formation. DHA acts 
on cyclooxygenases (COX), cytosolic phospholipase A2 (cPLA2), and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) [35, 36]. Deficiencies of lipids 
affect neural responses in CNS injuries, and this must predispose nerve cells to dys-
function [37]. According to previous findings, there are some investigations (Table 1) 
that have previously shown the effects of PUFAs in preclinical models.
3.1.3.2 Glutathione
Glutathione (GSH) is a tripeptide compound constituted by glutamine, 
glycine, and cysteine. The reduced form of GSH is glutathione-monoethyl-ester 
(GSHE), which is an endogenous, rechargeable antioxidant. Besides its anti-oxi-
dant functions, GSHE plays a role in regulation of apoptosis, and it is important 
for cellular defense against ROS [43, 44]. Some studies have reported that GSHE 
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diminishes SC LPO after SCI, while also acting as a vasodilator under condi-
tions of oxidative stress [44, 45]. In addition, GSHE plays an anti-excitotoxic 
role by inhibiting the binding ligands to ionotropic glutamate receptors under 
redox modulation, which have been involved in excitotoxicity after SCI. As a 
consequence of the reduction of GSH after an injury, there is neuronal loss in the 
SC, probably due to oxidative stress and mitochondrial dysfunction. Combined 
therapy of GSHE with A91 resulted in a better motor recovery and axonal sparing 
associated with a higher axonal myelination [46]. The use of GSHE could be an 
interesting alternative for SCI therapy; however, it should be strongly evaluated 
before its use in clinical trials.
3.1.4 Anti-apoptosis therapy
3.1.4.1 Zdevd-fmk
Caspase inhibitor Z-DEVD-fmk is a selective caspase-3 inhibitor that also has anti-
inflammatory properties. Anti-apoptosis compounds are used to block apoptotic cell 
death but also to inhibit cytokine production. Treatment of SCI with z-DEVD reduces 
secondary tissue damage, ischemic injury, preserves motor function, and provides 
neuroprotection via the inhibition of cell death in all of cell types in the SC [47, 48]. 
Low doses of z-DEVD-fmk combined with basic fibroblast growth factor (bFGF) 
reduce neurological deficit in ischemia, therefore providing neuroprotection [49].
3.1.4.2 z-LEHD-fmk
Caspase inhibitor z-LEHD-fmk acts as a selective caspase-9 inhibitor with anti-
apoptotic properties. This drug helps decreasing levels of apoptosis biochemical 
markers, reducing lesion size and remaining active during treatment to maintain 
its therapeutic effect. Treatment with z-LEHD-fmk helps to prevent apoptosis in 
a variety of cell types like neurons, astrocytes, oligodendrocytes, and microglia 
populations [50]. Further studies are needed to understand more about its effects 
and benefits in acute SCI.
3.1.5 Calpain inhibitors
Calpains belong to the family of calcium-dependent nonlysosomal cysteine 
proteases, which can be found expressed through the CNS. They are involved in 
Treatment outcome Ref.
α-linolenic acid (ALA) and DHA reduce lesion size and increase motor recovery and neuronal 
survival.
[34]
DHA reduces microglia activation in both ventral and dorsal horns and increases motor recovery, 
promoting beneficial functional effect in SCI.
[38]
ALA, combined with DHA, protects against neuronal necrosis and apoptosis. [39]
DHA induces a reduction in neutrophil number in SC epicenter. The administration confers 
histological protection and improves motor recovery.
[40]
Prophylactic therapy with ω-3 has shown a reduction in cellular vulnerability. Supporting 
functional recovery, there is also an increase in levels of protein kinase B/Akt and CREB.
[37, 
41]
DHA plus rehabilitation enhance a functional, anatomical, and synaptic plasticity in cervical SCI. [42]
Table 1. 
Polyunsaturated fatty acids in spinal cord injury.
Neuroprotection - New Approaches and Prospects
6
neurodegeneration, degradation of cytoskeleton, and apoptosis via caspase-3 due 
to its proteolytic activities, in SCI. The influx of Ca+2 stimulates Ca+2-dependent 
enzymes, within them are calpains, which seem to play a role in proteolysis by con-
tributing to apoptosis in CNS cells. The cell death decreases mRNA expression and 
transcription of myelin basic protein (MBP) and proteolipid protein (PLP), which 
are axonal neurofilament proteins [49, 51, 52]. The administration of a calpain 
inhibitor such as E-64-d (1 mg/kg) to injured rats blocks apoptosis and helps to 
re-establish MBP and PLP genes [51]. The administration of other calpain inhibitors 
such as SJA 6017 and calpeptin has demonstrated their ability to induce neuropro-
tection after SCI [53, 54]. Despite the study efforts and the promising therapeutic 
effects for functional neuroprotection, there are no clinical trials testing these 
drugs, so further studies are needed for the use of calpain inhibitors in patients.
3.1.6 Immunosuppressive or immunomodulatory drugs.
3.1.6.1 Inhibitors of cyclooxygenase
3.1.6.1.1 Indomethacin
Indomethacin, a nonsteroidal anti-inflammatory (NSAID) drug, acts as a 
nonselective cyclooxygenase inhibitor. It has shown that it inhibits the synthesis of 
prostaglandins and ameliorates the effects of secondary injuries like tissue necro-
sis in SCI [55–57]. RhoA is a convergent intracellular pathway that limits axonal 
growth; its inhibition with indomethacin prevents oligodendrocyte loss and induces 
myelination across damaged white matter [58]. Nevertheless, the administration of 
nonselective cyclooxygenase inhibitors is a controversial issue since these com-
pounds could inhibit platelet aggregation and may produce gastrointestinal ulcer-
ation [55]. Moreover, there is evidence that a single injection of indomethacin in SCI 
had a minimal effect on functional recovery and anatomical repair [57].
3.1.6.1.2 Meloxicam
Meloxicam is a drug derived from enolic acid, which inhibits prostaglandin 
biosynthesis under inflammatory conditions via the inhibition of COX-2. It has 
minimal gastric toxicity. Meloxicam has shown to reduce SCI-induced oxidative 
stress and exert neuroprotection by inhibiting LPO, GSH depletion, and DNA 
fragmentation [59, 60]. Despite these interesting results, meloxicam has not been 
further studied. Therefore, more studies are needed to know about its clinical 
management in SCI.
3.1.7 Immunophilin ligands
3.1.7.1 Cyclosporine A
Cyclosporine A (CsA) is an immunosuppressant agent compound formed by 11 
amino cyclic peptides, and it is obtained from Tolypocladium inflatum. CsA inhibits 
T-helper lymphocytes, cytotoxic and inflammatory responses in macrophages, 
inducible nitric oxide synthase (iNOs) expression avoiding the formation of nitric 
oxide (NO)-derived cytotoxic species, Cox-2 mRNA accumulation, tumor necrosis 
factor (TNFα) production and reduces cytokines and interleukins production (IL-1, 
IL-2, and IL-6). Also, CsA reduced the apoptosis of SC cells and increased the 
protein expression levels of cyclophilin-D (Cyp-D) and apoptosis-inducing factor 
(AIF) [61, 62]. This compound is capable of inducing motor recovery after SCI [63].
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3.1.7.2 Tacrolimus
Tacrolimus or FK506 is an immunosuppressant macrolide drug, isolated from 
Streptomyces tsukubaensis, and it is approved by The Food and Drug Administration 
(FDA) [64, 65]. An indirect neuroprotective effect results from its immunosuppres-
sant action on T-cells that infiltrate SCI, and this action modulates inflammation. 
On the other hand, FK506 inhibits caspase-3 and NF-kB, improving functional 
recovery with the increase of rostral axonal sparing and oligodendroglial survival 
[66, 67]. Additionally, this compound is capable of reducing FR and thereby 
LPO. These neuroprotective effects improve if the administration of FK506 is 
during the first 30 min after injury [65]. The studies suggest that FK506 might be a 
good drug for treating SCI in humans.
3.1.8 With neural derived peptides
Immunization with neural derived peptides (INDP) such as A91, a peptide 
derived from the 87–99 immunogenic sequence of myelin basic protein has shown 
to induce neuroprotection and motor recovery after SCI [68]. Its mechanism of 
action is related to the activation of T-lymphocytes inducing an anti-inflammatory 
Th2 response that allows microglia to differentiate into a M2 phenotype. Th2 
response is capable of producing brain-derived neurotrophic factor (BDNF), a 
molecule strongly related to tissue protection [69]. INDP has shown that anti-A91 
T-lymphocytes promote tissue protection by inhibiting the expression of iNOS, 
reducing ON production [68] and decrease LPO after SCI [70]. On the other hand, 
it has been shown that all these beneficial effects contribute to the preservation of 
neural tissue by preventing apoptosis [71], the survival of neurons in rubrospinal 
tract [72] and promoting a better neurological recovery in models of SCI [46]. 
Studies suggest that A91 might be an immune modulating treatment for SCI.
3.1.9 Metformin
Metformin is a hypoglycemic agent used for therapy of type 2 diabetes mel-
litus; it is an AMP-activated protein kinase (AMPK) agonist. Metformin also acts 
through signaling pathway of mTOR and p70S6K causing an inhibition of apoptosis 
and inflammation. This drug is also capable of stimulating autophagy and reduc-
ing expression of NF-kB-mediated inflammation [73, 74]. Studies indicate that 
long-term use of metformin has been proved effective as a pharmacological treat-
ment for some CNS disorders like Parkinson’s disease, Huntington’s disease, and 
ischemic brain injury. Using a rat model of traumatic SCI, the administration of 
metformin helps restoring the dysfunctional autophagy-lysosome pathways provid-
ing neuroprotection, decreasing neuronal death and mitigating apoptosis [75, 76]. 
The immediate administration of metformin after the injury showed diminishing 
complications, reflecting a decrease on histopathological signs of neuroinflamma-
tion, including TNFα and IL-1β inflammatory cytokines in the SC [73]. Although 
these outcomes are promising, subsequent studies are required to determine the risk 
ad optimal doses for the use of metformin on clinical studies.
3.1.10 Gonadal hormones
Androgens and estrogens are multi-active steroidal hormones that have neu-
roprotective effects in neural injuries; both testosterone and estradiol improve 
safeguard against apoptosis and promote motor and sensitive recovery. Also, 
reduce inflammation and FR generation and have been involved in regulating the 
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expression of cytoskeletal proteins, promoting them as an increasing in neurite 
outgrowth [77, 78]. Studies in rats treated with estradiol have shown a reduction 
in the lesion size, an increase in white matter sparing, and an improving in motor 
function [77, 79, 80]. On the other hand, testosterone has shown to exert similar 
but not identical effects; it is neuroprotective against apoptosis in oxidative stress 
[77, 78]. A study with young adult female rats implanted with testosterone-filled 
silastic capsules reported regressive changes in motoneuron and muscle morphol-
ogy after a SCI providing the possibility of improving motor function [81]. A 
study with administration of progesterone in rats improves neurological deficits 
and reduces inflammatory response. Prevents degeneration of motor neurons and 
reestablishes proliferation and differentiation of oligodendrocytes [82]. At the 
moment, investigations on the field conclude that gonadal hormones could be an 
effective alternative after SCI.
3.2 Clinical pharmacological therapies
Methylprednisolone, minocycline, GM-1-ganglioside, and glyburide are some of 
the most investigated pharmacological therapies in clinical settings.
3.2.1 Methylprednisolone
Methylprednisolone (MP) is a synthetic glucocorticoid, with anti-inflammatory 
and anti-oxidant effects [83, 84]. MP blocks the inflammatory cascade and disrupts 
neuron regeneration by inhibiting immunological cells [85, 86]. The potential 
neuroprotective effects of MP have been reported especially in the acute phase of 
SCI. According to some investigations, MP is capable of reducing FR production, 
Ca+2 influx, excitotoxicity, and immune-mediated phagocytosis over the course of 
hypoperfusion of SCI [87]. In addition, MP appears to have effect in apoptosis and 
autophagy regulation; however, the mechanisms are not clear [84]. While it remains 
the only option for acute SCI treatment in clinical settings, a debate regarding 
optimal dose, time of administration, efficacy, and adverse effects has dominated 
the field for years. There are three National Acute SCI Studies (NASCIS) and other 
clinical or biomedical investigations, in which the safety and efficacy of MP were 
assessed (Table 2) [88]. Despite the intense investigation, currently there is an 
important controversy regarding the real utility of this drug.
3.2.2 Minocycline
Minocycline is a second generation tetracycline, a semi-synthetic antibiotic 
able to cross blood brain barrier, and it can be used to treat rheumatoid arthritis 
[95, 96]. Minocycline has neuroprotective effects when administered during the 
acute neural trauma. Current data suggest that minocycline has anti-inflammatory, 
immunomodulatory, and neuroprotective effects. These beneficial actions are 
achieved as a result of the inhibition of iNOS matrix metalloproteinases (MMPs), 
PLA2, TNF-α, caspase-1, and caspase-3. Moreover, minocycline enhances Bcl-2 
and thus, reduces apoptosis, also, it decreases p38 mitogen-activated protein 
kinase (MAPK) phosphorylation and inhibits PARP-1 [97–100]. Other studies 
report that minocycline can bind to Ca+2 and Mg+, reduces reactive astrocytes to 
increase oligodendrocyte viability in white matter, and inhibits the activation of 
microglial cells [101, 102]. A multi-center phase II trial was performed to explore 
the neuroprotective effect of minocycline; however, the results of the study did 
not establish a real improvement in SCI. Authors suggest further investigations in a 
multi-center phase III trial [103].
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3.2.3 GM-1-ganglioside
Gangliosides (GM-1) are sialic acid-containing glycosphingolipids, pres-
ent in cell membranes of CNS cells, specifically in the external leaflet of plasma 
membranes. They participate in the repair and maintenance of CNS [104, 105]. A 
randomized placebo-controlled (Phase II) trial with administration of GM-1 within 
24 hours after injury was realized in 37 patients with SCI. The results of this study 
showed that GM-1 enhances the recovery of neurologic function after 1 year [104]. 
Further studies should be designed in order to provide more evidence about the 
efficacy of GM-1.
3.2.4 Glyburide
Glyburide (glibenclamide) is a FDA approved sulfonylurea drug widely used 
to treat type 2 diabetes; it has the ability to target receptor (SUR1) regulated Ca+2 
activated [ATP] cation (NCCa-ATP) channels [96, 106]. After SCI, there are small 
hemorrhagic lesions at the epicenter of gray matter. Glyburide diminishes the 
progressive hemorrhage necrosis by jamming the interaction between SUR-1 and 
preforming subunits of NCCa-ATP channels located in endothelial cells. In addi-
tion, improves neurological function [107]. Actually, a phase I/II clinical trial is cur-
rently under way to test the safety and neuroprotective effectiveness of glyburide in 
patients with SCI [88].
4. Nonpharmacological therapies (preclinical interventions)
The most common preclinical nonpharmacological therapies in the acute phase 
of SCI are antioxidants, growth factors, and transplant of cultured cells like neural 
stem cells (NSCs), bone marrow stem cells (BMSCs), olfactory ensheathing cells 
(OECs), and Schwann cells (SCs).
Treatment outcome Ref.
NASCIS I: Treatment with a dose 1.0 g daily promotes neurological recovery. The morbidity and 
mortality is increased.
[89]
NASCIS II: Administration of (30 mg/kg intravenous bolus plus 23 hour infusion of 5.4 mg/kg) 
during the first 8 hours after injury causes neurological recovery seen from 6 weeks after the SCI.
[86]
NASCIS III: Administration within 8 hours from the SCI, should maintain the administration for 
48 hours to improve neurological function.
[90]
Combination of riluzole and MP improves functional recovery and tissue sparing. In addition, 
beneficial effects on oxidative stress were observed.
[91]
MP may cause acute corticosteroid myopathy, at doses recommended by the NASCIS. [92]
High-dose MP inhibits glucocorticoid receptors as well as having effects in LPO; however, their 
beneficial effects are independent of LPO inhibition.
[55]
Administration of MP for treatment of SCI is not recommended. There is evidence that high-dose 
steroids are associated with harmful side effects including death.
[93]
A comparative study of MP vs. A91-immunization showed that A91-immunization has a better 
efficiency promoting motor recovery. Combining MP with A91-immunization allowed to observe 
that MP has a transient immunosuppressive effect that eliminated the beneficial actions of 
A91-immunization.
[94]
Table 2. 
Effects of methylprednisolone in spinal cord injury.
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4.1 Antioxidants
First damage in the acute phase of injury is generated in membranes, membranes 
which are susceptible to the attack of ROS and reactive nitrogen species (RNS). ROS 
are produced in metabolic and physiological processes of cells; however, they are 
overproduced by inflammatory response. ROS and RNS induce LPO, which leads 
to demyelinating processes. Among the nonpharmacological therapies to prevent 
damage from FR are nonenzymatic antioxidants like vitamins.
4.1.1 Vitamins
Vitamins are one of the main natural antioxidants. Table 3 shows some vitamins 
and their neuroprotective effect after SCI.
4.1.2 Resveratrol
Resveratrol is a natural polyphenolic compound that has exhibited beneficial 
health properties as well as antioxidant, anti-inflammatory, and antitumor 
effects. Resveratrol exerts a neuroprotective effect by regulating apoptosis [118]. 
Studies have shown that the anti-inflammatory effects of resveratrol are mediated 
mainly by sirtuin (SIRT) 1 [119, 120]. Resveratrol enhances locomotor recovery 
[121–123]. Furthermore, resveratrol increases nuclear factor erythroid 2-related 
factor (Nrf-2) activation, providing antioxidant effects [121]. Further inves-
tigation is needed in order to provide more evidence about the efficacy of this 
treatment.
Treatment Neuroprotection mechanism Ref.
Vitamin E Increases functional recovery.
Reduces cavitation and decreases FR, LPO, and glutathione 
peroxidase and improves functional recovery.
[108–
112]
Vitamin C Stops lipid hydroperoxyides formation and decreases membrane 
damage.
Reduces necrotic tissues and improves functional recovery in rats.
Inhibits ROS generation and LPO.
Decreases levels of proteins like NF-kB, iNOS, and COX-2.
Down-regulates the levels of TNFα and IL-1β.
Modulates antioxidant status and MPO activity
[113, 
114]
Vitamin 
C + fluoxetine
Co-treatment with vitamin C + fluoxetine inhibits the blood-SC 
barrier disruption after SCI.
Inhibits capillary fragmentation by reducing mRNA levels of MMP-9.
Prevents degradation of tight-junction proteins, inhibits infiltration 
of neutrophils and macrophages.
Inhibits apoptotic cell death and improves functional recovery.
[115]
Vitamin A Increases the expression of IL-1β, IL-6, and TNFα after SCI.
Systemic administration reduces early transcript levels of IL-1β, IL-6, 
and TNFα.
Reduces blood-SC-barrier permeability and improves functional 
recovery
[116]
Decreases levels of β-catenin, P120 catenin, occluding, and claudin5.
Inhibits endocytoplasmic reticulum stress and caspase-12 
expression.
[117]
Table 3. 
Vitamins in spinal cord injury.
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4.2 Growth factors
The use of growth factors like BDNF, transforming growth factor-β (TGF-β), 
and insulin-like growth factor-1 (IGF-1) as a therapy to improve morphological and 
behavioral outcomes after SCI has been topic of study of many investigations.
4.2.1 Brain-derived neurotrophic factor
BDNF exerts a relevant function in the repair of neural tissue and plastic-
ity in CNS [124, 125]. Nevertheless, recent studies have also shown that BDNF 
is capable of exerting neuroprotective effects. In acute phases of injury, several 
reports indicate that both, BDNF alone [126, 127] or in any combination [128, 129] 
has improved functional recovery, neuronal survival, and tissue preservation. 
Moreover, BDNF has potent antioxidant effects and may be involved in regulation 
of immune responses after an SCI [130]. BDNF after SCI requires careful selection 
to consider the location, mode, and time of application after an injury.
4.2.2 Transforming growth factor-β
TGF-β is a pleiotropic molecule with specific key functions in cell differentia-
tion, proliferation, migration, immunosuppression, and extracellular matrix 
metabolism [131]. TGF-β could also be contributing to neuroprotective mechanisms 
Therapy Neuroprotective effects Ref.
NSCs Increase functional recovery.
Reduction in neutrophils and M1 macrophages.
Downregulation of TNFα, IL-1 β, IL-6, and IL-12.
Improve functional recovery and reduce neuronal apoptosis, microglia 
activation, reduce pro-inflammatory cytokines like TNFα, IL-1β, and IL-6.
Improve locomotor and sensory function and increase mRNA expression 
of BDNF.
[141–
144]
BMSCs Improve locomotor function and tissue protection.
Increase the neurotrophic growth factor.
Stimulate M2 macrophage activation.
Reduce cystic cavities size and suppress glial scar formation.
[145–
148]
BMSCs + SCs Reduce the formation of the glial scar, remyelinate the injured axons, and 
promote functional recovery
[149]
BMSCs + 
IGF-1
Induce modulation of inflammatory cytokines and oxidative stress.
Increase functional recovery and reduce activation of glial fibrillary acidic 
protein and increase myelination 4 weeks following SCI.
[150]
BMSCs + 
OECs
Reduce apoptosis and increase locomotor recovery. [151]
OECs Reduce cavity size, increase the neurofilaments sprouting and serotonin 
axons, and improve functionality.
[152]
OECs + SCs Diminish astrocyte number, microglia/macrophage infiltration and 
expression of CCL2 and CCL3.
[153]
SCs Upregulate the expression of NOS, activate the NO-dependent cyclic-GMP 
pathway, which enhances neuronal survival.
Stimulate the expression of neural growth factor and BDNF.
Reduce inflammatory cytokines and ROS.
[154, 
155]
SCs + NSCs Promote neuronal differentiation, increase axonal regeneration/myelination, 
reduce neuronal loss, and improve functional recovery.
[156]
Table 4. 
Stem cell therapy in spinal cord injury.
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after SCI since it participates in the regulation of neuronal survival and orchestrates 
repairing processes in the CNS [132]. It has been previously observed that TGF-β 
administration reduces microglial activation and increases neuronal survival [133]. 
The early induction of TGF-β after SCI modulates the acute immune response, the 
formation of glial scar and improves functional recovery [134].
4.2.3 Insulin-like growth factor-1
IGF-1 belongs to the family of insulin-related peptides, and it is the mediator of 
the anabolic and mitogenic activity of the growth hormone [135]. Aside from this, 
IGF-1 acts as a strong antioxidant [136] and pro-survival [137] factor in the CNS 
since it diminishes caspase-9 and elevates Bcl2 [138]. Experimental studies have 
shown that IGF-1 reduces edema and the upregulation of iNOS after SCI [139]. In 
the same way, it has been suggested that IGF-1 and erythropoietin protect against 
ischemic SCI in rabbits [140]. Therefore, the beneficial properties of IGF-1 make 
this molecule an interesting neuroprotective strategy in the acute phase of SCI.
4.3 Stem cells
Stem cells have also been the focus of several investigations. Table 4 summarizes 
some of the neuroprotective effects exerted by stem cells like NSCs, BMSCs, OECs, 
and SCs.
5. Nonpharmacological therapies (clinical trials)
Nonpharmacological therapies with clinical studies are hence limited in acute 
phases of the injury.
5.1 Stem cells neural stem cells
Pilot studies cover the acute phase of SCI.
5.1.1 Neural stem cells
Transplants with human NSCs in phase I/IIa assessed the safety and neurological 
effects after SCI. Of 19 treated subjects, 17 were sensorimotor complete and two were 
motor complete and sensory incomplete. They demonstrated that 1 year after cell trans-
plantation, there was no evidence of SC damage, syrinx or tumor formation, neurologi-
cal deterioration, and exacerbating neuropathic pain or spasticity [157]. Additional 
studies should be designed in order to afford more evidence about the efficacy of NSCs.
5.1.2 Bone marrow stem cells
Regarding bone marrow stem cells (BMSC), an interesting study reported data 
from 20 patients with complete SCI who received transplants of BMSC. They showed 
improvement in motor and sensory functions [158]. In addition, a study with autolo-
gous BMSCs in three patients in the sub-acute phase of injury (<6 months of disease) 
demonstrated that, these cells could be safely administered through intrathecal 
injection in SCI patients [159]. Other study showed that 45.5% of transplanted patients 
presented improved neurological function. They showed some degree of improvement 
in sensitivity and motor function as well as in sexual function. In two patients, neuro-
pathic pain disappeared and bladder and bowel control increased [160]. Nevertheless, 
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more investigation through clinical trials is required with a larger population of 
patients before further conclusions can be drawn.
5.1.3 Olfactory ensheathing cells
Transplants with autologous OECs in three patients indicated that there were no 
adverse effects 1 year after transplantation. The neurosurgical process did not lead 
to any negative sequelae either during the operation or postoperatively. Additionally, 
they demonstrated the possibility of taking a nasal biopsy and reliably generating 
enough cells for transplantation within 4 weeks [161]. These observations suggest 
that autologous transplantation is safe but further researches are needed.
5.1.4 Schwann cells
A Phase I clinical trial with autologous human SCs was conducted to evaluate the 
safety of transplantation into the injury of six subjects with subacute SCI. There was 
no evidence of additional SC damage, mass lesion or syrinx formation. They con-
clude that it is feasible to identify eligible candidates, appropriately obtain informed 
consent, perform a peripheral nerve harvest to obtain SCs within 5–30 days of 
injury, and perform intra-spinal transplantation of highly purified autologous SCs 
within 4–7 weeks of injury [162]. Studies in acute phases using SCs are very few: 
therefore, more studies are needed in this area.
5.2 Physical therapy
Timing as a specific prognostic factor in rehabilitation results and confirms 
that early specific rehabilitation treatment is associated with greater improvement. 
Several studies investigate the early rehabilitation as a therapeutic strategy to 
improve locomotor function, some of them have even shown physical functional 
independence [163–165]. Other studies indicated that in acute SCI physical therapy 
of body weight support on a treadmill and defined overground mobility therapy did 
not produce different results [166]. Further studies are required to afford conclusive 
results.
6. Conclusions
In conclusion, there are several pharmacological and nonpharmacological 
treatments that have been tested in preclinical and clinical phases. However, so far 
have not yielded fully satisfactory results; even using combined therapies. Further 
studies are needed in order to identify novel therapeutic targets and strategies that 
provide a better medical care avoiding complications.
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